Assistive Artificial Intelligence in Epilepsy and Its Impact on Epilepsy Care in Low- and Middle-Income Countries
Brain Sciences · 01.05.2025 · 15 (5) · 481
DOI: 10.3390/brainsci15050481 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 01.05.2025. Verfasst von Nabin Koirala und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Yale University, New Haven, CT 06511, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation.
Abstract (Originalsprache)
Epilepsy, one of the most common neurological diseases in the world, affects around 50 million people, with a notably disproportionate prevalence in individuals residing in low- and middle-income countries (LMICs). Alarmingly, over 80% of annual epilepsy-related fatalities occur within LMICs. The burden of the disease assessed using Disability Adjusted Life Years (DALYs) shows that epilepsy accounts for about 13 million DALYs per year, with LMICs bearing most of this burden due to the disproportionately high diagnostic and treatment gaps. Furthermore, LMICs also endure a significant financial burden, with the cost of epilepsy reaching up to 0.5% of the Gross National Product (GNP) in some cases. Difficulties in the appropriate diagnosis and treatment are complicated by the lack of trained medical specialists. Therefore, in these conditions, adopting artificial intelligence (AI)-based solutions may improve epilepsy care in LMICs. In this theoretical and critical review, we focus on epilepsy and its management in LMICs, as well as on the employment of AI technologies to aid epilepsy care in LMICs. We begin with a general introduction of epilepsy and present basic diagnostic and treatment approaches. We then explore the socioeconomic impact, treatment gaps, and efforts made to mitigate these issues. Taking this step further, we examine recent AI-related developments and their potential as assistive tools in clinical application in LMICs, along with proposals for future directions. We conclude by suggesting the need for scalable, low-cost AI solutions that align with the local infrastructure, policy and community engagement to improve epilepsy care in LMICs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Yale University, New Haven, CT 06511, USA.
- Brain Imaging Research Core, University of Connecticut, Storrs, CT 06269, USA.
- Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.
- Nepal Applied Mathematics and Informatics Institute for Research, Kathmandu 44700, Nepal.
- Gilling's School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA.
- Institut du Cerveau-Paris Brain Institute, 75013 Paris, France.
ORCID-Profile: Nabin Koirala, Abdul Rauf Anwar, Dumitru Ciolac, Muthuraman Muthuraman
Förderung
- German Research Foundation
Zitieren
APA
Koirala, N., Adhikari, S. R., Adhikari, M., Yadav, T., Anwar, A. R., Ciolac, D., Shrestha, B., Adhikari, I., Khanal, B., & Muthuraman, M. (2025). Assistive Artificial Intelligence in Epilepsy and Its Impact on Epilepsy Care in Low- and Middle-Income Countries. Brain Sciences, 15(5), 481. https://doi.org/10.3390/brainsci15050481
Vancouver
Koirala N, Adhikari SR, Adhikari M, Yadav T, Anwar AR, Ciolac D, et al. Assistive Artificial Intelligence in Epilepsy and Its Impact on Epilepsy Care in Low- and Middle-Income Countries. Brain Sciences. 2025;15(5):481. doi:10.3390/brainsci15050481
BibTeX
@article{Koirala2025,
author = {Koirala, Nabin and Adhikari, Shishir Raj and Adhikari, Mukesh and Yadav, Taruna and Anwar, Abdul Rauf and Ciolac, Dumitru and Shrestha, Bibhusan and Adhikari, Ishan and Khanal, Bishesh and Muthuraman, Muthuraman},
title = {Assistive Artificial Intelligence in Epilepsy and Its Impact on Epilepsy Care in Low- and Middle-Income Countries},
journal = {Brain Sciences},
year = {2025},
volume = {15},
number = {5},
pages = {481},
doi = {10.3390/brainsci15050481}
}
EUVIMED